Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.
Nebulized amphotericin B (AMB) combined with intravenous AMB was studied in persistently leukopenic rats with invasive pulmonary aspergillosis. Pulmonary concentrations of AMB after aerosol treatment were substantially higher than after intravenous liposomal AMB. Nebulized liposomal AMB in addition to intravenous AMB resulted in significantly prolonged survival compared to controls.
|Keywords||Amphotericin B/*administration & dosage/pharmacology, Animals, Antibiotics, Antifungal/*administration & dosage/pharmacology, Aspergillosis/*drug therapy, Aspergillus fumigatus/*drug effects, Biological Markers/metabolism, Injections, Intravenous, Liposomes, Lung Diseases, Fungal/*drug therapy/microbiology, Nebulizers and Vaporizers/microbiology, Rats, Severity of Illness Index, Treatment Outcome|
|Persistent URL||dx.doi.org/10.1128/AAC.50.5.1852-1854.2006, hdl.handle.net/1765/14000|
Ruijgrok, E.J., Fens, M.H., Bakker-Woudenberg, I.A.J.M., van Etten, E.W.M., & Vulto, A.G.. (2006). Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.. Antimicrobial Agents and Chemotherapy, 50(5), 1852–1854. doi:10.1128/AAC.50.5.1852-1854.2006